N. Hamblett

1.1k total citations
18 papers, 824 citations indexed

About

N. Hamblett is a scholar working on Pulmonary and Respiratory Medicine, Epidemiology and Surgery. According to data from OpenAlex, N. Hamblett has authored 18 papers receiving a total of 824 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 3 papers in Epidemiology and 2 papers in Surgery. Recurrent topics in N. Hamblett's work include Cystic Fibrosis Research Advances (11 papers), Respiratory viral infections research (3 papers) and Neonatal Respiratory Health Research (3 papers). N. Hamblett is often cited by papers focused on Cystic Fibrosis Research Advances (11 papers), Respiratory viral infections research (3 papers) and Neonatal Respiratory Health Research (3 papers). N. Hamblett collaborates with scholars based in United States and United Kingdom. N. Hamblett's co-authors include Bonnie W. Ramsey, Pamela L. Zeitlin, David Waltz, Richard B. Moss, Margaret Rosenfeld, Moira L. Aitken, David M. Rodman, L. Terry Spencer, Carlos Milla and Alison E. Heald and has published in prestigious journals such as American Journal of Respiratory and Critical Care Medicine, Clinical Infectious Diseases and CHEST Journal.

In The Last Decade

N. Hamblett

17 papers receiving 796 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
N. Hamblett United States 11 508 194 193 170 99 18 824
Isabelle Honoré France 14 433 0.9× 175 0.9× 147 0.8× 81 0.5× 169 1.7× 29 777
Christopher L. Case United States 23 172 0.3× 339 1.7× 668 3.5× 28 0.2× 45 0.5× 86 1.8k
Joshua C. Eby United States 14 208 0.4× 189 1.0× 186 1.0× 41 0.2× 125 1.3× 28 701
H. Blau Israel 10 306 0.6× 231 1.2× 96 0.5× 31 0.2× 140 1.4× 19 591
Marie Johannesson Sweden 18 554 1.1× 63 0.3× 179 0.9× 46 0.3× 65 0.7× 31 866
Christian Østergaard Denmark 19 82 0.2× 352 1.8× 228 1.2× 14 0.1× 116 1.2× 28 890
Hans‐Peter Hauber Germany 15 333 0.7× 80 0.4× 154 0.8× 18 0.1× 24 0.2× 34 748
Gerald W. Fernald United States 17 151 0.3× 431 2.2× 73 0.4× 42 0.2× 81 0.8× 31 786
J Weber Germany 15 146 0.3× 336 1.7× 73 0.4× 34 0.2× 149 1.5× 58 758
John Ervin United States 13 52 0.1× 270 1.4× 104 0.5× 65 0.4× 179 1.8× 20 677

Countries citing papers authored by N. Hamblett

Since Specialization
Citations

This map shows the geographic impact of N. Hamblett's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by N. Hamblett with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites N. Hamblett more than expected).

Fields of papers citing papers by N. Hamblett

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by N. Hamblett. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by N. Hamblett. The network helps show where N. Hamblett may publish in the future.

Co-authorship network of co-authors of N. Hamblett

This figure shows the co-authorship network connecting the top 25 collaborators of N. Hamblett. A scholar is included among the top collaborators of N. Hamblett based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with N. Hamblett. N. Hamblett is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
VanDevanter, Donald R., Colin O’Rourke, Michael W. Konstan, John P. Clancy, & N. Hamblett. (2025). Differences in pulmonary exacerbation risks among CF subpopulations. Journal of Cystic Fibrosis. 25(2). 204–209.
2.
Sanders, Don B., N. Hamblett, M. Rosenfeld, et al.. (2023). 607 Characteristics of individuals in the United States ineligible for ivacaftor and elexacaftor-tezacaftor-ivacaftor. Journal of Cystic Fibrosis. 22. S323–S323. 1 indexed citations
3.
Hamblett, N., Alex H. Gifford, Margaret Kloster, et al.. (2023). 106 Impact of discontinuing hypertonic saline and dornase alfa in people with cystic fibrosis established on elexacaftor-tezacaftor-ivacaftor: A SIMPLIFY ancillary study. Journal of Cystic Fibrosis. 22. S55–S56. 1 indexed citations
4.
Khan, Umer, et al.. (2021). A comparison of clinic and home spirometry as longtudinal outcomes in cystic fibrosis. Journal of Cystic Fibrosis. 21(1). 78–83. 31 indexed citations
5.
Cogen, Jonathan D., Frankline Onchiri, N. Hamblett, et al.. (2021). Association of Intensity of Antipseudomonal Antibiotic Therapy With Risk of Treatment-Emergent Organisms in Children With Cystic Fibrosis and Newly Acquired Pseudomonas Aeruginosa. Clinical Infectious Diseases. 73(6). 987–993. 5 indexed citations
6.
VanDevanter, Donald R., N. Hamblett, Noah Simon, Joseph McIntosh, & Michael W. Konstan. (2020). Evaluating assumptions of definition-based pulmonary exacerbation endpoints in cystic fibrosis clinical trials. Journal of Cystic Fibrosis. 20(1). 39–45. 13 indexed citations
7.
Gifford, Alex H., et al.. (2019). P279 Withdrawing existing chronic therapies in people with cystic fibrosis who benefit from highly effective CFTR modulator drugs. Journal of Cystic Fibrosis. 18. S136–S136. 1 indexed citations
8.
Bilton, Diana, T. Pressler, Marco Cipolli, et al.. (2013). PHASE 3 EFFICACY AND SAFETY DATA FROM RANDOMIZED, MULTICENTER STUDY OF LIPOSOMAL AMIKACIN FOR INHALATION (ARIKACE) COMPARED WITH TOBI (R) IN CYSTIC FIBROSIS PATIENTS WITH CHRONIC INFECTION DUE TO PSEUDOMONAS AERUGINOSA. Pediatric Pulmonology. 48. 290–290. 15 indexed citations
9.
Simon, Tamara D., Kathryn B. Whitlock, Jay Riva-Cambrin, et al.. (2012). Revision Surgeries Are Associated With Significant Increased Risk of Subsequent Cerebrospinal Fluid Shunt Infection. The Pediatric Infectious Disease Journal. 31(6). 551–556. 49 indexed citations
10.
Thorell, Emily A., et al.. (2011). Treatment and Microbiology of Repeated Cerebrospinal Fluid Shunt Infections in Children. The Pediatric Infectious Disease Journal. 30(9). 731–735. 36 indexed citations
11.
Ashlock, Melissa A., Robert J. Beall, N. Hamblett, et al.. (2009). A Pipeline of Therapies for Cystic Fibrosis. Seminars in Respiratory and Critical Care Medicine. 30(5). 611–626. 20 indexed citations
12.
Sabbatini, Gina, et al.. (2009). Protocol for Improved NPD Performance for International Trials.. A1792–A1792. 1 indexed citations
13.
Moss, Richard B., David M. Rodman, L. Terry Spencer, et al.. (2004). Repeated Adeno-Associated Virus Serotype 2 Aerosol-Mediated Cystic Fibrosis Transmembrane Regulator Gene Transfer to the Lungs of Patients With Cystic Fibrosis. CHEST Journal. 125(2). 509–521. 292 indexed citations
14.
Gibson, Ronald L., Julia Emerson, Sharon McNamara, et al.. (2003). Significant Microbiological Effect of Inhaled Tobramycin in Young Children with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine. 167(6). 841–849. 243 indexed citations
15.
Piedra, Pedro A., Stanley G. Cron, Alan M. Jewell, et al.. (2003). Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: a multi-center trial in children with cystic fibrosis. Vaccine. 21(19-20). 2448–2460. 72 indexed citations
16.
Lumley, Thomas & N. Hamblett. (2003). Asymptotics for Marginal Generalized Linear Models With Sparse Correlations. Collection of Biostatistics Research Archive. 12 indexed citations
17.
Noone, Peadar G., N. Hamblett, Frank J. Accurso, et al.. (2001). Safety of aerosolized INS 365 in patients with mild to moderate cystic fibrosis: Results of a phase I multi‐center study. Pediatric Pulmonology. 32(2). 122–128. 31 indexed citations
18.
Noone, Peadar G., N. Hamblett, Frank J. Accurso, et al.. (2001). Safety of aerosolized INS 365 in patients with mild to moderate cystic fibrosis: Results of a phase I multi‐center study. Pediatric Pulmonology. 32(2). 122–128. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Isabelle Honoré Breakdown of academic impact, for papers by Christopher L. Case Breakdown of academic impact, for papers by Joshua C. Eby Breakdown of academic impact, for papers by H. Blau Breakdown of academic impact, for papers by Marie Johannesson Breakdown of academic impact, for papers by Christian Østergaard Breakdown of academic impact, for papers by Hans‐Peter Hauber Breakdown of academic impact, for papers by Gerald W. Fernald Breakdown of academic impact, for papers by J Weber Breakdown of academic impact, for papers by John Ervin
Rankless by CCL
2026